A Study of IBI362 9 mg in Chinese Adults With Obesity
NCT06164873 on ClinicalTrials.gov · last registry update 2024-08-27
462 participants. The sponsor logged completion for 27 June 2025. Primary outcome, as filed: Percent Change from Baseline in Body Weight. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- UNKNOWN
- Phase
- P3
- Drug
- mazdutide
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Enrollment
- 462
- Started
- 2023-12-27
- Primary completion
- 2025-06-27 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-31 | Status changed | ACTIVE_NOT_RECRUITING → UNKNOWN |
Primary outcome
Percent Change from Baseline in Body Weight
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.